Status and phase
Conditions
Treatments
About
To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China
Sex
Ages
Volunteers
Inclusion criteria
-Patients must have relapsing remitting multiple sclerosis
Exclusion criteria
Patients with:
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal